Allied Market Research

2024

Immunomodulators Market

Immunomodulators Market Size, Share, Competitive Landscape and Trend Analysis Report, by Product and, by Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Immunomodulators are substances that alter the immune response by decreasing the responsiveness of the immune system to make antibodies or sensitized cells. These cells identify and react with the antigen that instigated their production. Some of the immunomodulators are corticosteroids, thymosin, cytotoxic agents, and immunoglobulins. Few of the immunomodulators are naturally present in the body, while some of these are obtained from pharmacological preparations.

The major factors that drive the market growth are increasing usage of monoclonal antibodies to treat diseases such as sclerosis, Crohns disease, rheumatoid arthritis & others, and the rising prevalence of cancer. In addition, availability of effective product pipeline of the companies involved in R&D of immunomodulators further fuels the market growth. However, the presence of stringent regulations involved in the approval procedure for immunomodulator antibodies pose entry difficulties for small-scale manufacturers, less availability of tumor necrosis factor (TNF) inhibitors, and high costs associated with them act as restraints for the market growth. In addition, rising awareness regarding the availability of such immunomodulators is anticipated to provide lucrative growth opportunities for the market.

The report segments the immunomodulators market based on product, application, and region. Based on product, the market is segmented into immunosuppressants and immunostimulants. Based on immunosuppressants, the market is segmented into antibodies, calcineurin inhibitors, glucocorticoids, antimetabolites, and others. Based on immunostimulants, the market is segmented into vaccines, antibodies, and others. Based on application, the market is segmented into oncology, respiratory, human immunodeficiency virus (HIV), and others. Regionally, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Benefits

  • The study provides an in-depth analysis of the immunomodulators market, with current trends and future estimations to elucidate imminent investment pockets.
  • It presents a quantitative analysis¬†to enable stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by product type elucidates various forms of available immunomodulators.
  • Key players have been profiled and their strategies thoroughly analyzed, which predict the competitive outlook of the market.
  • By region, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Immunomodulators Market Report Highlights

Aspects Details
icon_5
By Product
  • IMMUNOSUPPRESSANTS
    • Antibodies
    • Calcineurin Inhibitors
    • Glucocorticoids
    • Antimetabolites
    • Others
  • IMMUNOSTIMULANTS
    • Vaccines
    • Antibodies
    • Others
icon_6
By Application
  • Oncology
  • Respiratory
  • Human Immunodeficiency Virus (HIV)
  • Others
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, UK, France, Spain, Italy, Rest of Europe)
  • Asia-Pacific  (Japan, China, India, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Argentina, Rest of LAMEA)
icon_8
Key Market Players

BRISTOL-MYERS SQUIBB COMPANY, MERCK & CO., INC., PFIZER INC., ELI LILLY AND COMPANY, NOVARTIS AG, ABBOTT LABORATORIES, AMGEN, INC., JOHNSON & JOHNSON, F. HOFFMANN-LA ROCHE LTD., BIOGEN INC.

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Immunomodulators Market

Global Opportunity Analysis and Industry Forecast, 2023-2032